The landscape of dementia prognosis has progressed considerably with the appearance of refined biomarkers, which include amyloid PET scans, tau imaging, and blood-centered tests that may detect Alzheimer's pathology several years just before indicators arise. When these technological innovations represent outstanding progress in knowing neurodegene